J. J. Kiladjian - Inst Rech St Louis, Univ Paris

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 66 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

S196: ropeginterferon alfa-2b achieves patient-specific treatment goals in polycythemia vera: final results from the proud-pv/continuation-pv studies

H. Gisslinger,C. Klade,P. Georgiev, D. Krochmalczyk,L. Gercheva-Kyuchukova,M. Egyed,P. Dulicek,A. Illes,H. Pylypenko,L. Sivcheva, J. Mayer, V. Yablokova, V. Empson, K. Krejcy,H. Hasselbalch,R. Kralovics,J.-J. Kiladjian

HemaSphere（2022）

引用2浏览0引用

P980: jak2v617f-dependent down regulation of shp1 expression participates in the selection of mpn cells in the presence of tgfβ

C. Aoun, N. Salomao,N. Maslah, S. Awan Toor, G. Letort, P. Gou,J.-J. Kiladjian,S. Giraudier,B. Cassinat

HemaSphere (2022): 870-871

引用0浏览0引用

Effect of treatment with fedratinib on spleen volume and symptoms in myelofibrosis patients with significant splenomegaly: post-hoc analyses of the JAKARTA and JAKARTA2 trials

A. Reiter,Kiladjian J.-J,A. Tefferi,F. Passamonti,A. Vannucchi,M. Talpaz,F. Cervantes,C. N. Harrison,R. A. Mesa,J. Mascarenhas,N. Schaap,S. Verstovsek,T. Devos,S. Rose,J. Zhang,O. Sy,A. Pardanani

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022): 277-277

引用0浏览0引用

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

B. Mora,P. Guglielmelli,A. Kuykendall,M. Maffioli,G. Rotunno,R. S. Komrokji,F. Palandri,J.-J. Kiladjian,A. Iurlo,G. Auteri,D. Cattaneo,V. De Stefano,S. Salmoiraghi,T. Devos,F. Cervantes,M. Merli,A. Campagna,G. Benevolo, M. Brociner,F. Albano,J. Gotlib,M. Caramella,M. Ruggeri,D. M. Ross, F. Orsini, C. Pessina, I. Colugnat, F. Pallotti,T. Barbui,L. Bertù,M. G. Della Porta,A. M. Vannucchi,F. Passamonti

HemaSphere (2022): 885-886

引用0浏览0引用

TP53-mutant selection by MDM2 inhibition: Single cell analysis and predictive assay

N. Maslah,E. Verger,S. Giraudier, M. Chea,L. Benajiba,J. Soret-Dulphy,B. Cassinat,J. J. Kiladjian

FUNDAMENTAL & CLINICAL PHARMACOLOGY（2022）

引用0浏览0引用

Managing Hematological Cancer Patients During the COVID-19 Pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

ESMO OPENno. 2 (2022)

引用29浏览0WOS引用

S193: genomic and functional impact of tp53 inactivation in jak2v617f myeloproliferative neoplasms: a transgenic mouse model approach

P. GOU, D. LIU, E. Lauret,N. Maslah, V. Montcuquet,V. meignin,J.-J. Kiladjian,B. Cassinat,S. Giraudier

HemaSphere（2022）

引用0浏览0引用

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

J.-J. Kiladjian,A. Tefferi,F. Passamonti,A. Vannucchi,M. Talpaz,F. Cervantes,C. N. Harrison,R. A. Mesa,J. Mascarenhas,N. Schaap,S. Verstovsek,T. Devos, S. Rose,J. Zhang,O. Sy,A. Pardanani

HemaSphere (2022): 931-932

引用0浏览0引用

INDEPENDENCE: Recruiting phase 3 study to evaluate the efficacy and safety of luspatercept versus placebo in patients with myelofibrosis, concomitant JAK2 inhibitor therapy, and transfusion dependence

H. K. Al-Ali,R. A. Mesa,C. Harrison,J. -J Kiladjian,S. Verstovsek, F. Sanabria, C. Mazur,P. Martin-Regueira, T. C. Young,F. Passamonti

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022): 276-276

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn